In conclusion, complement activation, likely due to ULvWF-induced APC dysregulation, may contribute to the pathophysiology and clinical manifestations of TTP, especially hemolysis and likely, thrombocytopenia. The gene discussed is APC; the disease is thrombotic thrombocytopenic purpura.